Regeneron Pharmaceuticals reported solid third quarter results for 2025, with robust sales growth driven by Dupixent and Libtayo, complemented by EYLEA HD achieving record revenue despite ongoing affordability challenges.
- Dupixent generated $4.9 billion in global net sales, a 26% increase year-over-year, with dominance in multiple indications and growing patient base.
- Libtayo sales reached $365 million, up 24% year-over-year, bolstered by a recent FDA approval for use in high-risk adjuvant cutaneous squamous cell carcinoma.
- EYLEA HD sales hit an all-time high of $431 million in the U.S., driven by increased physician demand, though impacted by pricing pressures and market affordability issues.
- Ongoing regulatory challenges with prefilled syringe approvals for EYLEA HD could affect future growth potential; alternate filling plans set for submission by January 2026.
- Significant R&D progress announced with positive Phase III results across diverse therapeutic areas, enhancing pipeline momentum ahead of upcoming pivotal studies.
Community Discussion